Formosa Pharmaceuticals, Inc.’s Post

At the end of 2023, both Ionis Pharmaceuticals, Inc. and Dicerna Pharmaceuticals, Inc. received FDA approvals for two new synthetic #oligonucleotide drugs. Ionis's eplontersen offers a new treatment option for certain forms of polyneuropathy, while Dicerna's nedosiran targets hyperoxaluria. With even more #oligo drugs in development, it's an important time for new bioanalytical research. Our team has been focused on refining oligonucleotide extraction techniques. Their work aims to enhance bioanalysis measurements through sensitive direct injection #LCMS techniques that employ rapid, organic-assisted proteinase K digestion with microplate WAX #SPE. Promising results are coming in for both HRMS and tissue work. For those interested in the technical aspects of these advancements, we're hosting a global webinar on February 20th. It will be an opportunity to learn more and ask questions. 🖥 Webinar Link: https://lnkd.in/gWq7n44m Nikunj Tanna, Makda Araya, Joe Fredette, Waters Corporation, Waters | Andrew Alliance, #LifeatWaters

JT and Torii Pharmaceutical Co., Ltd. announced the initial results of a Phase 3 comparative study relative to pediatric patients with atopic dermatitis in Japan treated with JTE-061(tapinarof). We will aim to submit a manufacturing and marketing application for JTE-061 cream in Japan, based on the results of this and other clinical studies. For detailed results, please refer to the press release: https://lnkd.in/g2_9jhfi #JT #Torii Pharmaceutical #Pharma #tapinarof   小児アトピー性皮膚炎患者を対象とした現在開発中のJTE-061(tapinarof)について、日本国内で実施中の第Ⅲ相臨床試験（比較試験）の速報結果を得ました。 今後、本試験の成績等をもとに、日本国内における製造販売承認申請を目指します。 詳細な速報結果については、プレスリリースをご覧ください: https://lnkd.in/gt2KMrSX

Island Pharmaceuticals Ltd (ASX:ILA) CEO and managing director Dr David Foster joins Jonathan Jackson in the Proactive studio to discuss the company’s $1.95 million raise and developments around ISLA-101, its leading drug candidate. Dr Foster provides an overview of ISLA-101, focusing on its intended purpose and potential impact, before speaking about the allocation of funds, particularly towards the analysis of data from the Phase 1 dose-escalation study. He also discusses the outcomes of this study, including the safety and tolerability of the drug, and what these results signify for the company. Money will also be used to advance a Phase 2 clinical trial. Dr Foster details the steps involved in this and what the company aims to achieve in this next phase of research. Finally, he looks ahead to the upcoming quarter, discussing the milestones and developments Island Pharmaceuticals anticipates. Watch at #Proactive #ProactiveInvestors #ASX #ILA #Biotech #Biopharmaceuticals #AntiVirals #DengueFever https://lnkd.in/eZF35GZM

𝐑𝐚𝐩𝐢𝐝 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞 𝐢𝐬 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐢𝐧 𝐬𝐚𝐯𝐢𝐧𝐠 𝐥𝐢𝐯𝐞𝐬 𝐟𝐫𝐨𝐦 𝐜𝐡𝐞𝐦𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐭𝐡𝐫𝐞𝐚𝐭𝐬. The latest JSTO in the News article, 𝐁𝐫𝐞𝐚𝐭𝐡𝐢𝐧𝐠 𝐑𝐨𝐨𝐦, highlights DTRA JSTO's collaboration with researchers to develop a game-changing solution. This FDA-approved, small-molecule therapeutic called 3,4-Diaminopyridine Phosphate (3,4 DAPP) offers rapid recovery from botulinum neurotoxin (BoNT) paralysis in our #JointForce. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐡𝐞𝐫𝐞: ➡️https://bit.ly/3JEl5wc 𝐓𝐀𝐆:🫱🏽🫲🏽 Battelle Southwest Research Institute MRIGlobal Aclairo Pharmaceutical Development Group Catalyst Pharmaceuticals, Inc. #ChemicalDefense #BiologicalDefense #JSTO #ProtectingOurJointForce #NationalSecurity

Suven Pharma to acquire stake in Sapala Organics Day #85 of covering Pharma Developments. 💊News Buzz.! Suven Pharmaceuticals said that it will acquire 100% stake of Sapla Organics Private Limited. 💊How are they planning to do this.? So initially, Suven Pharmaceuticals will acquire 67.5% of Sapala Organics Following the FY 2026-27, Suven Pharma will purchase remaining shares through secondary transactions. 💊What does Sapla Organics do.? Sapala Organics is a CDMO specialising in oligonucleotides and nucleic acid building blocks such as Phosphoramidites, Nucleosides, drug delivery compounds including GalNAc, and Pseudouridine. 💊How did the market react to this.? Today Suven Pharmaceuticals closed at 719.15 (7.67%) above the previous day. I will provide the source of the article in the comment section below. By the way today is the 85th day of me deep diving into the pharmaceutical industry. I will be sharing insights from this industry on a regular basis. So please do follow me (Krishna Raj K) for such insights. #Finance #Linkedin #India

Did you know that for centuries, people have harnessed the healing powers of mushrooms? Prema Sagara, a faculty for our Psilocybin Guides Certification, shares that while MDMA and Ketamine are man-made pharmaceutical drugs, psilocybin can be found naturally in mushrooms worldwide — and its healing properties are different in a number of important ways. Prema shares more in this short video - "Working With Psilocybin Is Different From Other Psychedelics" https://lnkd.in/guk2bECK

The success of blockbuster drugs is often accompanied by costly R&D investments and exclusive patent protection. As the patents on these drugs expire, the market will be re-shuffled. Below is a list of 10 drugs with upcoming patent(partly) expirations in 2024: Ozempic (Semaglutide) - May 2024 Farxiga (Dapagliflozin) - April 2024 Cabometyx (Cabozantinib) - September 2024 Xifaxan (Rifaximin) - June 2024 Latuda (lurasidone HCl) - February 2024 Entresto (Sacubitril/Valsartan) - May 2024 Symbicort (budesonide, formoterol) - November 2024 Lynparza (Olaparib) - October 2024 AbilifyMaintenaKit (Aripiprazole) - October 2024 Xarelto (Rivaroxaban) - November 2024 Discussion is welcome in the comments section, please point out any errors. #semaglutide #dapagliflozin #API #pharmaceutical #generics

China Art of war : Chinese policy makers aim to make China's domestic biotechnology industry the medicine cabinet of the world.To a large extent they have already succeeded in achieving dominance in the lower end of pharmaceutical and medical technology value chain.80% of the API of drugs in the American market come from the overseas primarily from China and India.in older drugs with low profit margin Chinese drugmakers have often taken over production entirely from western companies.chinese manufacturers are already the sole suppliers of many API(Active pharmaceutical ingredients)lower end drugs

Another Exciting News for all 🔊 ✨ WBCIL Publishes Pioneering Research on Enhanced Iron Supplementation with Liposomal Technology in the World Journal of Pharmaceutical Sciences!! We are thrilled to announce the publication of our latest research on liposomal iron titled "LIPOSOMAL IRON: A NOVEL APPROACH FOR IMPROVED IRON SUPPLEMENTATION, MANUFACTURED BY WEST BENGAL CHEMICAL INDUSTRIES LTD" in World Journal of Pharmaceutical Sciences. This study underscores the advantages of liposomal technology in pharmaceuticals, particularly how it enhances the bioavailability and stability of iron supplements. At WBCIL, we take pride in offering liposomal iron with an encapsulation efficiency exceeding 85%, ensuring superior delivery and efficacy. Authored by Dr.Poulami Gupta Banerjee, Dr. Atanuka Paul, Dr. Manoj Mukhopadhyay, Kumari Lily, and Dr. Utpalendu Banerjee, this publication highlights our commitment to advancing innovative solutions in healthcare. . . . #Wbcil #researchanddevelopment #iron #irondeficiency #fightagainstirondeficiency

Hainan Poly Pharmaceutical Co., Ltd. recently received an order from an American customer for iopamidol injection (intravascular administration) in specifications of 51% (50ml), 61% (30ml), 61% (100ml), and 76% (100ml). The order amount is equivalent to over 100 million yuan, and the order fulfillment period is 8 months. As the only generic drug company selling iopamidol in the US market, Poly Pharmaceuticals directly competes with the original research company. Nowadays, the acquisition of a large order of 100 million yuan is the full affirmation and recognition of Poly Pharmaceuticals' iopamidol injection by the US market. #generic #iopamidol